Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based Microtest Laboratories will manufacture and provide supporting pharmaceutical testing services for immunotherapeutic vaccine; Nexvax2 by ImmusanT in the company's expected upcoming clinical trial.
Subscribe to our email newsletter
Microtest will also provide testing services to ImmusanT supporting its drug product manufacture, including method transfer activities, complete final product release testing, storage and stability.
ImmusanT raised $20m recently to progress the development of their technology, Nexvax2, to treat celiac disease.
Microtest Laboratories Project Management director Alex Mello said Microtest provides a faster and risk-minimizing alternative to subcontracting with a variety of providers at multiple locations.
"We deliver the flexibility, solutions, and problem-solving experience manufacturers must have to ensure the most expeditious release of their product," Mello added.